Bluejay completes planned clinical studies for symphony il-6 test

Acton, mass., july 06, 2022 (globe newswire) -- bluejay diagnostics, inc. (nasdaq: bjdx) (“bluejay”, “the company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the symphony il-6 test (the “test”). results of these studies will be published at the 2022 aacc annual scientific meeting being held july 26th to 28th in chicago.
BJDX Ratings Summary
BJDX Quant Ranking